Castrate-resistant Prostate Cancer Market Introduction and Overview
According to SPER market research, ‘Global Castrate-resistant Prostate Cancer Market Size- By Therapy – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Castrate-resistant Prostate Cancer Market is predicted to reach 30.78 billion by 2034 with a CAGR of 8.91%.
Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to conventional hormone therapy. In CRPC, the cancer grows despite low testosterone levels in the body, which are usually the result of surgical or medicinal castration.
Restraints:The limited effectiveness of treatments and their high costs are hindering market growth for CRPC. Many treatments are too expensive for patients without insurance, making them hard to access. The severe side effects from treatments like chemotherapy and immunotherapy can negatively affect patients’ quality of life, making it hard to stick to their plans. Although there are various treatments for CRPC, not all patients will respond to them. Some may develop resistance, complicating disease management and prolonging survival challenges.
Scope of the Report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Therapy.
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.
Companies Covered
Sanofi, Johnson & Johnson Services, Inc, Pfizer, Inc, Astellas Pharma, Inc, Bayer AG.
Castrate-resistant Prostate Cancer Market Segmentation:
By Therapy:Based on the Therapy, Global Castrate-resistant Prostate Cancer Market is segmented as; Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy.
By Region:This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Castrate-resistant Prostate Cancer Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Castrate-resistant Prostate Cancer Market
- 7. Global Castrate-resistant Prostate Cancer Market, By Therapy (USD Million) 2021-2034
- 7.1. Chemotherapy
- 7.2. Hormonal Therapy
- 7.3. Immunotherapy
- 7.4. Radiotherapy
- 8. Global Castrate-resistant Prostate Cancer Market, (USD Million) 2021-2034
- 8.1. Global Castrate-resistant Prostate Cancer Market Size and Market Share
- 9. Global Castrate-resistant Prostate Cancer Market, By Region, (USD Million) 2021-2034
- 9.1. Asia-Pacific
- 9.1.1. Australia
- 9.1.2. China
- 9.1.3. India
- 9.1.4. Japan
- 9.1.5. South Korea
- 9.1.6. Rest of Asia-Pacific
- 9.2. Europe
- 9.2.1. France
- 9.2.2. Germany
- 9.2.3. Italy
- 9.2.4. Spain
- 9.2.5. United Kingdom
- 9.2.6. Rest of Europe
- 9.3. Middle East and Africa
- 9.3.1. Kingdom of Saudi Arabia
- 9.3.2. United Arab Emirates
- 9.3.3. Qatar
- 9.3.4. South Africa
- 9.3.5. Egypt
- 9.3.6. Morocco
- 9.3.7. Nigeria
- 9.3.8. Rest of Middle-East and Africa
- 9.4. North America
- 9.4.1. Canada
- 9.4.2. Mexico
- 9.4.3. United States
- 9.5. Latin America
- 9.5.1. Argentina
- 9.5.2. Brazil
- 9.5.3. Rest of Latin America
- 10. Company Profile
- 10.1. Sanofi
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
- 10.2. Johnson & Johnson Services, Inc
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
- 10.3. Pfizer, Inc
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
- 10.4. Astellas Pharma, Inc
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
- 10.5. Bayer AG
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
- 10.6. Others
- 11. Conclusion
- 12. List of Abbreviations
- 13. Reference Links
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook